Matt joined OUP in 2013. Along with the other Managing Partners, Matt is responsible for overseeing and approving all Partnership investments and all other Partnership and organizational activities. Alongside Bill Harrington, M.D., Matt co-manages OUP’s life science investment activities and team. Matt has been involved with OUP’s investment in several portfolio companies including Biohaven Pharma (NYSE: BHVN), Synthorx (acquired by Sanofi), Kura Oncology (NASDAQ: KURA), Cell Design Labs (acquired by Gilead), Kate Tx (acquired by Novartis), Arrakis Therapeutics, PMV Pharma (NASDAQ: PMVP), Context Therapeutics (NASDAQ: CNTX), Sana Biotechnology (NASDAQ: SANA), and others.  

Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma and private equity. 

Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from Penn State University.